News Release

<< Back
Proteon Therapeutics to Present at Two Upcoming Investor Conferences

WALTHAM, Mass., Sept. 2, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced that Company management will present a corporate overview at the following upcoming investor conferences:

  • The Baird 2015 Healthcare Conference on September 9, 2015 at 2:35 p.m. ET in New York, NY; and
     
  • The 22nd Annual NewsMakers in the Biotech Industry on September 10, 2015 at 3:00 p.m. ET in New York, NY.

A live audio webcast of the Baird 2015 Healthcare Conference presentation can be accessed by visiting the "Events & Presentations" page within the Investor and Media section of the Company's website at www.proteontherapeutics.com. A replay of the webcast will be archived on the Proteon website following the presentation. 

About Proteon Therapeutics
Proteon Therapeutics is committed to improving the health of patients with kidney and vascular diseases through the development of novel, first-in-class therapeutics. Proteon's lead product candidate, vonapanitase (formerly PRT-201), is an investigational treatment intended to improve arteriovenous fistula (AVF) patency, the period of time during which an AVF remains open with adequate blood flow to enable hemodialysis. Proteon is currently evaluating vonapanitase in two Phase 3 clinical trials in patients with chronic kidney disease (CKD) undergoing surgical creation of a radiocephalic AVF for hemodialysis and has completed a Phase 1 clinical trial in patients with symptomatic peripheral artery disease (PAD). For more information, please visit www.proteontherapeutics.com.

Investor Relations Contact
George Eldridge, Proteon Therapeutics, Senior Vice President and Chief Financial Officer
781-890-0102
geldridge@proteontherapeutics.com

Media Contact
Chris Erdman or Lynnea Olivarez, MacDougall Biomedical Communications
781-235-3060
proteon@macbiocom.com

Proteon logo

Proteon Therapeutics Inc.